Dr. Jaideep Behari, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 120
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
PA license MD428371
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC Jameson New Castle, PA
- Washington Hospital, the Washington, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 120
- Services billed
- 185
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 51 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 49 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xifaxan (rifaximin) Other prescribers in Pittsburgh, PA | 96 |
| Tacrolimus Other prescribers in Pittsburgh, PA | 88 |
| Ursodiol Other prescribers in Pittsburgh, PA | 59 |
| Vemlidy (tenofovir alafenamide) | 37 |
| Pantoprazole Sodium Other prescribers in Pittsburgh, PA | 35 |
| Carvedilol Other prescribers in Pittsburgh, PA | 35 |
| Mycophenolate Mofetil Other prescribers in Pittsburgh, PA | 33 |
| Prednisone Other prescribers in Pittsburgh, PA | 23 |
| Lactulose Other prescribers in Pittsburgh, PA | 23 |
| Furosemide Other prescribers in Pittsburgh, PA | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $73.63 in total to this clinician.
| Madrigal Pharmaceuticals | $73.63 |
|---|
| Food and Beverage | $73.63 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $220,177 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Rhythm Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.